Major Events - Cambridge Technology (06166) sets the offer price for H-shares at HKD 68.88 per share [1] - Sany Heavy Industry (06031) sets the offer price for H-shares at HKD 21.30 per share [1] - Hengrui Medicine (01276) receives approval for the launch of HR20031 tablets [1] - Shanghai Pharmaceuticals (02607) subsidiary becomes the holder of the marketing authorization for amisulpride orally disintegrating tablets [1] - Fosun Pharma (02196) receives registration approval for Delarobert tablets and Delarobert granules [1] - WuXi AppTec (02359) plans to sell 100% equity of Kande Hongyi and Jinshi Medicine [1] - Hengfu Holdings (00643) receives a buyout offer at a discount of approximately 79.20% and will resume trading on October 27 [1] Operating Performance - Chifeng Jilong Gold Mining (06693) reports Q3 net profit of CNY 951 million, a year-on-year increase of 140.98% [1] - WuXi AppTec (02359) reports a net profit of CNY 12.076 billion for the first three quarters, up 84.84% year-on-year [1] - Huaxin Cement (06655) reports a net profit of CNY 2.004 billion for the first three quarters, a year-on-year increase of 76.01% [1] - Luoyang Molybdenum (03993) reports a net profit of approximately CNY 14.28 billion for the first three quarters, up 72.61% year-on-year [1] - Goldwind Technology (02208) reports a net profit of approximately CNY 2.584 billion for the first three quarters, a year-on-year increase of 44.21% [1] - CITIC Securities (06030) reports a net profit of approximately CNY 23.159 billion for the first three quarters, up 37.86% year-on-year [1] - Kingdee International (00268) reports annual recurring revenue of approximately CNY 3.86 billion from subscription services for the first three quarters, a year-on-year increase of about 18% [1] - China Nonferrous Mining (01258) estimates a profit of approximately USD 356 million for the first three quarters, a year-on-year increase of about 13% [1] - Chongqing Bank (01963) reports a net profit of CNY 4.879 billion for the first three quarters, a year-on-year increase of 10.19% [1] - China Resources Cement (01313) reports a profit attributable to shareholders of CNY 331 million for the first three quarters, a year-on-year increase of 7.3% [1] - China Shenhua Energy (01088) reports a net profit of CNY 41.366 billion for the first three quarters, a year-on-year decrease of 13.8% [1] - Haohai Biological Technology (06826) reports a net profit of approximately CNY 305 million for the first three quarters, a year-on-year decrease of 10.63% [1] - Great Wall Motors (02333) reports a net profit of CNY 2.298 billion for the third quarter, a year-on-year decrease of 31.23% [1] - China Heart and Heart Fertilizer (01866) reports a net profit of approximately CNY 800 million for the first three quarters, a year-on-year decrease of 47.86% [1] - China National Building Material (03323) reports a net profit of CNY 2.96 billion for the first three quarters [1] - GAC Group (02238) reports a net loss of approximately CNY 4.312 billion for the first three quarters, a shift from profit to loss year-on-year [1] - China Overseas Development (00688) reports revenue of CNY 103 billion and operating profit of CNY 13.15 billion for the first three quarters [1] - Haifeng International (01308) reports revenue of approximately USD 2.459 billion for the first three quarters, a year-on-year increase of approximately 16.6% [1] - China Energy Engineering (03996) reports a cumulative new contract amount of CNY 992.775 billion for the first three quarters, a year-on-year increase of 0.4% [1] E-commerce Performance - Li Ning (02331) reports high double-digit growth in its e-commerce virtual store business for the third quarter [2]

氨磺必利口崩片是赛诺菲（Sanofi）公司于 1986 年在法国上市的氨磺必利片的改良剂型，用于治疗成 人精神分裂症。 上药中西成为氨磺必利口崩片的上市许可持有人，进一步丰富了公司产品线，有利于提升公司市场竞争 力。 格隆汇10月24日丨上海医药(601607.SH)公布，公司下属上海上药中西制药有限公司（称"上药中西"） 收到国家药品监督管理局颁发的《药品补充申请批准通知书》（通知书编号：2025B04804、 2025B04815），其同意将氨磺必利口崩片（称"该药品"）上市许可持有人变更为上海上药中西制药有 限公司。 ...

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration to change the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Pharmaceutical Zhongxi Pharmaceutical Co., Ltd [1][2]. Group 1: Drug Information - Drug Name: Amisulpride Orally Disintegrating Tablets - Dosage Form: Tablet - Specifications: 50mg, 0.2g - Registration Classification: Chemical Drug - Approval Numbers: National Drug Approval Code H20250041, H20250042 - Approval Conclusion: Change of marketing authorization holder from "Shanghai Zezheng Pharmaceutical Technology Co., Ltd." to "Shanghai Pharmaceutical Zhongxi Pharmaceutical Co., Ltd." [2]. Group 2: Market Context - Amisulpride Orally Disintegrating Tablets is an improved formulation of Amisulpride Tablets, which was launched by Sanofi in France in 1986 for the treatment of adult schizophrenia [3]. - As of the date of the announcement, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [4]. - According to IQVIA data, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [5]. Group 3: Company Impact - The change in marketing authorization holder for Amisulpride Orally Disintegrating Tablets enhances the product line of Shanghai Pharmaceuticals and is expected to improve the company's market competitiveness [6].

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of a change in the marketing authorization holder for Amisulpride orally disintegrating tablets to its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received the approval from the National Medical Products Administration for the change of marketing authorization holder [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] Group 1: Company Developments - The marketing authorization holder for Amisulpride Orally Disintegrating Tablets has been officially changed to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] - The company submitted the registration application for the change of marketing authorization holder to the National Medical Products Administration in September 2025, which has been accepted [1] - The company has invested approximately 31.5 million yuan in the development of this drug as of the date of the announcement [1] Group 2: Market Context - Amisulpride Orally Disintegrating Tablets is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for the treatment of adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd. (referred to as "Shiyou"), has received the approval notice from the National Medical Products Administration for the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou [1] Group 1 - The approval notice includes notification numbers: 2025B04804 and 2025B04815 [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration to change the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Pharmaceuticals Zhongxi Pharmaceutical Co., Ltd. This move is expected to enhance the company's product line and market competitiveness [1]. Group 1 - The National Medical Products Administration issued a "Drug Supplement Application Approval Notice" allowing the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets [1]. - Amisulpride Orally Disintegrating Tablets is an improved formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1]. - The change in marketing authorization holder to Shanghai Pharmaceuticals Zhongxi is anticipated to enrich the company's product offerings and strengthen its competitive position in the market [1].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. (referred to as "Shiyou Zhongxi"), has received a notification from the National Medical Products Administration (NMPA) approving the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shiyou Zhongxi [1] Group 1 - The NMPA has granted approval for the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets [1] - Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - Shiyou Zhongxi submitted the registration application for the change of marketing authorization holder to the NMPA in September 2025, which has been accepted [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration approving the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. [1] Group 1 - The Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, which were originally launched by Sanofi in France in 1986 for the treatment of adult schizophrenia [1] - The application for the change of marketing authorization holder was submitted to the National Medical Products Administration in September 2025 and has been accepted [1]